
    
      Study XP055 is a multicenter, open-label, 52-week extension study of XP13512 (Gabapentin
      Enacarbil [GEn]) given once daily to eligible subjects with Restless Legs Syndrome (RLS) who
      had previously completed 1 of the following studies and met eligibility criteria: XP052
      (110963 [NCT00298623]), XP053 (111460 [NCT00365352]), XP081 (111462 [NCT01332305]), and XP083
      (111463 [NCT01332318]).
    
  